Slootbeek, Peter H. J. http://orcid.org/0000-0002-5635-919X
Kloots, Iris S. H.
Smits, Minke
van Oort, Inge M.
Gerritsen, Winald R.
Schalken, Jack A. http://orcid.org/0000-0001-8274-7797
Ligtenberg, Marjolijn J. L. http://orcid.org/0000-0003-1290-1474
Grünberg, Katrien
Kroeze, Leonie I.
Bloemendal, Haiko J.
Mehra, Niven http://orcid.org/0000-0002-4794-1831
Article History
Received: 24 August 2021
Revised: 16 November 2021
Accepted: 1 December 2021
First Online: 15 December 2021
Change Date: 24 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-022-01765-y
Competing interests
: IvO: advisory role (compensated and institutional): Bayer, Astellas, Janssen and MSD/AstraZeneca. Research support (institutional): ‘Astellas, Janssen, Bayer. WG: speakers’ fees: Bayer and MSD. Advisory boards: Bristol-Myers Squibb, Astellas, Bayer, Sanofi, and Amgen. Research grant: Bayer, Astellas, and Janssen-Cilag. JS: Speaker honorarium: Astellas, Bayer. ML: advisory role (compensated and institutional): ‘AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Illy, Merck Sharp & Dohme, Novartis, Roche. Research support (institutional): ‘AstraZeneca, Bristol-Myers Squibb. KG: advisory role: Bayer, Roche, Bristol-Myers Squibb, AstraZeneca, Amgen. Collaborations with Bristol-Myers Squibb, Milestone, Sakura, Illumina. NM: advisory role (compensated and institutional): ‘Roche, MSD, BMS, Bayer, Astellas and Janssen’. Research support (institutional): ‘Astellas, Janssen, Pfizer, Roche and Sanofi’ Genzyme. Travel support: ‘Astellas, MSD’. The remaining authors declare no competing interests.
: No ethics approval was needed for this study. This study is in accordance with the Declaration of Helsinki. All sequenced patients outside of routine care provided written informed consent.
: This study does not contain traceable individual person’s data.